Literature DB >> 8633039

Converting cancer genes into killer genes.

L T Da Costa1, J Jen, T C He, T A Chan, K W Kinzler, B Vogelstein.   

Abstract

Over the past decade, it has become clear that tumorigenesis is driven by alterations in genes that control cell growth or cell death. Theoretically, the proteins encoded by these genes provide excellent targets for new therapeutic agents. Here, we describe a gene therapy approach to specifically kill tumor cells expressing such oncoproteins. In outline, the target oncoprotein binds to exogenously introduced gene products, resulting in transcriptional activation of a toxic gene. As an example, we show that this approach can be used to specifically kill cells overexpressing a mutant p53 gene in cell culture. The strategy may be generally applicable to neoplastic diseases in which the underlying patterns of genetic alterations or abnormal gene expression are known.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8633039      PMCID: PMC39510          DOI: 10.1073/pnas.93.9.4192

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Separation of DNA binding from the transcription-activating function of a eukaryotic regulatory protein.

Authors:  L Keegan; G Gill; M Ptashne
Journal:  Science       Date:  1986-02-14       Impact factor: 47.728

2.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5.

Authors:  F L Graham; J Smiley; W C Russell; R Nairn
Journal:  J Gen Virol       Date:  1977-07       Impact factor: 3.891

3.  A vector for expressing GAL4(1-147) fusions in mammalian cells.

Authors:  I Sadowski; M Ptashne
Journal:  Nucleic Acids Res       Date:  1989-09-25       Impact factor: 16.971

4.  Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms.

Authors:  P D Jeffrey; S Gorina; N P Pavletich
Journal:  Science       Date:  1995-03-10       Impact factor: 47.728

Review 5.  The two-hybrid system: an assay for protein-protein interactions.

Authors:  S Fields; R Sternglanz
Journal:  Trends Genet       Date:  1994-08       Impact factor: 11.639

6.  Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells.

Authors:  D I Linzer; A J Levine
Journal:  Cell       Date:  1979-05       Impact factor: 41.582

7.  Effects of the tricyclic nucleoside 6-amino-4-methyl-8-(beta-D-ribofuranosyl)- pyrrolo[4,3,2-de]pyrimido[4,5-c]pyridazine on the viability and cell cycle distribution of L1210 cells in vitro.

Authors:  L L Wotring; J E Passiatore; J L Roti Roti; J L Hudson; L B Townsend
Journal:  Cancer Res       Date:  1985-12       Impact factor: 12.701

Review 8.  Relationship of p53 to the control of apoptotic cell death.

Authors:  M Oren
Journal:  Semin Cancer Biol       Date:  1994-06       Impact factor: 15.707

Review 9.  Molecular foundations of cancer: new targets for intervention.

Authors:  J E Karp; S Broder
Journal:  Nat Med       Date:  1995-04       Impact factor: 53.440

10.  A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine.

Authors:  O Boussif; F Lezoualc'h; M A Zanta; M D Mergny; D Scherman; B Demeneix; J P Behr
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-01       Impact factor: 11.205

View more
  3 in total

1.  Codominant interference, antieffectors, and multitarget drugs.

Authors:  A Varshavsky
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

2.  Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the beta-catenin signaling activity.

Authors:  Lan Zhou; Naili An; Rex C Haydon; Qixin Zhou; Hongwei Cheng; Ying Peng; Wei Jiang; Hue H Luu; Pantila Vanichakarn; Jan Paul Szatkowski; Jae Yoon Park; Benjamin Breyer; Tong-Chuan He
Journal:  Cancer Lett       Date:  2003-04-25       Impact factor: 8.679

3.  Use of E. coli Purine Nucleoside Phosphorylase in the Treatment of Solid Tumors.

Authors:  William B Parker; Eric J Sorscher
Journal:  Curr Pharm Des       Date:  2017-11-08       Impact factor: 3.116

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.